Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab in relapsed/refractory mantle cell lymphoma
NCT05564052Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Events Leading to Discontinuation of Treatment at 12 months, Treatment Emergent Adverse Events Leading to Discontinuation of Treatment: Monotherapy Arm at 6 months and 8 more. Started Dec 2022; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05564052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564052.